While few studies have been published regarding the impact of ARID2 mutations in NSCLC, it is worth noting that a composite analysis of five clinical cohorts treated with ICI at MSKCC (n = 2272) showed a numerical trend towards improved PFS (8.3 vs. 4.1 months, HR = 0.79, p = 0.4; n = 349) and OS (36 vs. 11 months, HR = 0.60, p = 0.097; n = 344) when comparing mutated to wild‐type ARID2 cases, but the differences did not reach statistical significance [13]. Here, ARID2 is linked to non-small cell lung carcinoma.